A Randomized, Double-Blind, Placebo-Controlled Single-Ascending Dose and Multiple-Ascending Dose Phase 1 Study of SL-325 in Healthy Volunteers
Latest Information Update: 19 Sep 2025
At a glance
- Drugs SL 325 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors Shattuck Labs
Most Recent Events
- 01 May 2025 According to Shattuck Labs Media Release, First patient in for the SAD portion of the trial expected in the third quarter of 2025.
- 27 Mar 2025 According to Shattuck Labs Media Release, complete enrollment of this trial expected in the second quarter of 2026.
- 06 Jan 2025 New trial record